Monitor for actual CTA submission to Health Canada and any subsequent regulatory acceptance or clinical hold notices. The lack of concrete partnership agreements or funding details means this filing does not alter the company's cash runway or near-term dilution risk.
Price Chart
Executive Summary
XORTX announced plans to file a Clinical Trial Application (CTA) with Health Canada for its XRx-026 gout program (XORLO), aiming to conduct part one of the XRX-OXY-102 study in Canada to accelerate data for a future U.S. NDA. The company also noted increased inquiries from potential commercialization partners but has no agreements in place. This is a procedural regulatory update with no new clinical data or financial figures.
Key Facts
- Planned CTA submission to Health Canada for XRx-026 (XORLO) gout program
- Two-part clinical study XRX-OXY-102 evaluating XORLO, a proprietary oxypurinol formulation
- Part one to be conducted in Canada to accelerate data for planned U.S. NDA filing with FDA
- Company has received increased inquiries from potential commercialization partners but no agreements entered
- No financial data, clinical results, or regulatory milestones achieved in this filing
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company with no revenue or earnings reported
Risk Factors
- CTA may be delayed, rejected, or subject to additional data requests by Health Canada
- XRX-OXY-102 study may not proceed as planned or may yield negative results
- No assurance that commercialization partner discussions will result in a transaction
- Company requires additional capital to fund development programs and operations
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006540 |
| Document: f6k_100826.htm | 0001171843-26-006540 |
| Document: 0001171843-26-006540-index-headers.html | 0001171843-26-006540 |
| Document: 0001171843-26-006540-index.html | 0001171843-26-006540 |
| Document: 0001171843-26-006540.txt | 0001171843-26-006540 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $1.41 | awaiting T+20 | — | $1.06 (−24.82%) |
Sep 18, 2026 5w ago | 6-K | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $1.06 (−44.79%) |
Sep 18, 2026 5w ago | Press Release | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $1.06 (−44.79%) |
Sep 4, 2026 7w ago | 6-K | $2.31 $1.70 | ▲ +26.41% | ▲ +27.01% | $1.06 (+54.11%) |
Aug 28, 2026 8w ago | 6-K | $2.34 $1.71 | ▼ −26.86% | ▼ −27.12% | $1.06 (−54.66%) |
Aug 3, 2026 12w ago | 6-K | $2.16 $2.16 | · 0.00% | ▲ +1.24% | $1.06 (−50.93%) |
Jul 29, 2026 12w ago | 6-K | $2.06 $2.22 | ▲ +7.67% | ▲ +2.65% | $1.06 (−48.54%) |
Jun 15, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $1.06 (−51.60%) |
Jun 12, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $1.06 (−51.60%) |
May 19, 2026 23w ago | 6-K / PRESS-RELEASE | $2.32 $2.15 | ▲ +7.33% | ▲ +8.31% | $1.06 (+54.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers